Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas-Reference-Cited by-同舟云学术

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas

Published:2015-09-18 Issue:15 Volume:85 Page:1325-1331
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Alentorn Agustí,Dehais Caroline,Ducray François,Carpentier Catherine,Mokhtari Karima,Figarella-Branger Dominique,Chinot Olivier,Cohen-Moyal Elisabeth,Ramirez Carole,Loiseau Hugues,Elouahdani-Hamdi Selma,Beauchesne Patrick,Langlois Olivier,Desenclos Christine,Guillamo Jean-Sébastien,Dam-Hieu Phong,Ghiringhelli François,Colin Philippe,Godard Joel,Parker Fabrice,Dhermain Frédéric,Carpentier Antoine F.,Frenel Jean-Sebastien,Menei Philippe,Bauchet Luc,Faillot Thierry,Fesneau Mélanie,Fontaine Denys,Motuo-Fotso Marie-Jeannette,Vauleon Elodie,Gaultier Claude,Le Guerinel Caroline,Gueye Edouard-Marcel,Noel Georges,Desse Nicolas,Durando Xavier,Barrascout Eduardo,Wager Michel,Ricard Damien,Carpiuc Ioana,Delattre Jean-Yves,Idbaih Ahmed

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference15 articles.

1. Anaplastic oligodendroglial tumors

2. International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

3. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

4. Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

5. Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased UBD Is a Potential Diagnostic and Prognostic Biomarker in Glioma;Environmental Toxicology;2024-08-18

2. The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?;Neuro-Oncology;2024-06-24

3. Exploring the Cause of Survival Disparities in EGFR-Mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19Del and L858R Mutation Subtypes;Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry;2024-06

4. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification;HISTOL HISTOPATHOL;2023

5. Cyclin-Dependent Kinase Inhibitor 2A/B Homozygous Deletion Prediction and Survival Analysis;Brain Sciences;2023-03-25